Agenus EBITDA Margin 2010-2022 | AGEN

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Agenus (AGEN) over the last 10 years. The current EBITDA margin for Agenus as of March 31, 2022 is .
Agenus EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $0.31B $0.04B 12.26%
2021-12-31 $0.30B $0.03B 10.81%
2021-09-30 $0.31B $0.06B 20.85%
2021-06-30 $0.07B $-0.16B -228.99%
2021-03-31 $0.09B $-0.12B -145.88%
2020-12-31 $0.09B $-0.11B -125.00%
2020-09-30 $0.09B $-0.11B -117.39%
2020-06-30 $0.10B $-0.11B -112.37%
2020-03-31 $0.09B $-0.12B -136.05%
2019-12-31 $0.15B $-0.06B -41.72%
2019-09-30 $0.12B $-0.08B -68.03%
2019-06-30 $0.12B $-0.07B -63.48%
2019-03-31 $0.12B $-0.05B -42.61%
2018-12-31 $0.04B $-0.12B -316.22%
2018-09-30 $0.04B $-0.11B -276.92%
2018-06-30 $0.03B $-0.11B -393.10%
2018-03-31 $0.02B $-0.13B -741.18%
2017-12-31 $0.04B $-0.10B -233.33%
2017-09-30 $0.04B $-0.09B -217.50%
2017-06-30 $0.04B $-0.09B -224.39%
2017-03-31 $0.04B $-0.09B -197.73%
2016-12-31 $0.02B $-0.10B -443.48%
2016-09-30 $0.03B $-0.10B -408.00%
2016-06-30 $0.03B $-0.08B -278.57%
2016-03-31 $0.03B $-0.09B -329.63%
2015-12-31 $0.03B $-0.08B -320.00%
2015-09-30 $0.02B $-0.08B -415.79%
2015-06-30 $0.01B $-0.08B -535.71%
2015-03-31 $0.01B $-0.05B -454.55%
2014-12-31 $0.01B $-0.04B -525.00%
2014-09-30 $0.01B $-0.03B -516.67%
2014-06-30 $0.01B $-0.03B -620.00%
2014-03-31 $0.00B $-0.03B -1000.00%
2013-12-31 $0.00B $-0.02B -800.00%
2013-09-30 $0.00B $-0.02B -550.00%
2013-06-30 $0.00B $-0.02B -475.00%
2013-03-31 $0.00B $-0.02B -425.00%
2012-12-31 $0.02B $-0.01B -31.25%
2012-09-30 $0.02B $-0.01B -31.25%
2012-06-30 $0.02B $-0.01B -31.25%
2012-03-31 $0.02B $-0.00B -25.00%
2011-12-31 $0.00B $-0.02B -400.00%
2011-09-30 $0.00B $-0.02B -400.00%
2011-06-30 $0.00B $-0.02B -400.00%
2011-03-31 $0.00B $-0.02B -400.00%
2010-12-31 $0.00B $-0.02B -450.00%
2010-09-30 $0.00B $-0.02B -450.00%
2010-06-30 $0.00B $-0.02B -475.00%
2010-03-31 $0.00B $-0.02B -550.00%
2009-12-31 $0.00B $-0.02B -575.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.436B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00